Trump to slash funding for flagship US HIV programme by 40pc
America is proposing to cut its flagship anti-HIV programme by almost 40 per cent next year, according to new budget details that reveal sweeping reductions to global health spending.
Details from Donald Trump's 2026 budget request show nearly a two-fifths fall in funding for the United States President's Emergency Plan for Aids Relief (Pepfar).
The long-running programme is estimated to have saved more that 20 million lives in the past two decades, and is often cited as one of the world's most successful public health schemes.
A recent analysis published in the Lancet found that as many as half a million more children could die from Aids by the end of the decade because of disruptions to Pepfar.
The details on global health funding for the State Department, USAID agency, Centres for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH) also show deep cuts elsewhere.
Analysis by the San Francisco-based KFF health policy charity found the government departments were planning a 55 per cent cut in separate tuberculosis funding, a 47 per cent cut in malaria funding and a 92 per cent cut in maternal health funding.
The proposal also withdraws all £221m ($300m) given to Gavi, the vaccine alliance which provides jabs to children in poor countries.
In total, the request for money for the American government's main global health funding account is £2.8bn ($3.8bn) in 2026, down from £7.4bn ($10bn) in 2025.
Setting out the cuts, the State Department said the request for money 'eliminates funding for programmes that do not make Americans safer, such as family planning and reproductive health, neglected tropical diseases, and non-emergency nutrition'.
Mr Trump's government upended US aid spending days after taking office, saying it would suspend all aid while projects were reviewed.
It then proceeded to close hundreds of aid programmes, including Pepfar projects, resulting in lay-offs for thousands of health workers, particularly in Africa.
The budget proposals now give a clear indication that Mr Trump intends to continue with sharp cuts and will quash any hopes that the funding taps could be switched back on again.
A State Department explanation of the budget request uses the phrase 'America First' 37 times as it explains a new focus on cutting costs and protecting US national interests.
For the 2026 fiscal year, which begins on Oct 1, the budget proposals request £2.1bn ($2.9bn) for Pepfar, a 38 per cent reduction from the £3.5bn ($4.7bn) requested in 2025.
The State department said that after spending a total of £88bn ($120bn) in the past two decades, it was now focussing on finding a responsible 'off ramp' to hand over responsibility for the campaign against HIV to countries themselves.
'This [budget] request will allow the United States to accelerate the transition of HIV control programmes to recipient countries and increase international ownership of efforts to fight HIV/Aids.'
Some projects may still be paid for by other government funds, but overall the KFF analysis found the budget included 'significant reductions in global health funding including the elimination of some programs and activities'.
The details will prove a severe disappointment to aid projects who had hoped that despite Mr Trump's rhetoric, there was a chance funding could be renewed in the new fiscal year.
Public health officials argue that continuing to fund global health projects to stamp out infectious diseases is still in America's best interests as infections often cross borders.
One executive at a major South African anti-HIV organisation said: 'Nobody wins unless we all win. No one can make it out of this alone. This is how we achieve epidemic control.'
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Why tariffs are already driving some healthcare premiums higher
Related video above: How patients and doctors can reduce healthcare costs (NEXSTAR) – Despite the focus on the price of cars, iPhones and other consumer goods, the Trump administration's tariffs are starting to drive up prices in an entirely different industry – healthcare. On Monday, Matt McGough, with nonprofit health policy organization KFF, wrote that several individual insurance companies have already notified state regulators that they will be raising premiums to offset the potential impact of tariffs on pharmaceuticals. Trump hasn't yet targeted pharmaceuticals with tariffs, but has repeatedly brought it up, including on Monday aboard Air Force One. 'We're going to be doing pharmaceuticals very soon,' Trump said, according to Reuters. 'That's going to bring all the companies back, into America.' In a May filing, the Independent Health Benefits Corporation (IHBC) said it was submitting a premium rate change of 38.4% for 2026, 'primarily due to increased costs due to inflation and tariffs, and changes in risk adjustment.' An IHBC spokesperson told Axios that roughly 3% of that increase was to directly account for the impact of tariffs, specifically on drug prices. McGough notes that there are other insurers who either haven't specifically mentioned the potential effect of tariffs or who declined to include an offsetting increase in 2026 premium rates. 'A large proportion of medical goods currently comes from international sources, including pharmaceuticals, medical devices and personal protective equipment, as well as other low-margin, high-use essentials like syringes, needles and blood pressure cuffs,' Tina Freese Decker, board chair of the American Hospital Association, wrote in a May post. 'Tariffs on these items could impact patient care by jeopardizing the availability of vital medications and essential health care devices. They also could raise costs for hospitals and heighten shortages and supply chain disruptions.' Meantime, millions of Affordable Care Act (ACA) enrollees could see an over 75% average increase in premiums if Biden-era subsidies aren't extended by Congress before they expire at the end of the year, according to KFF estimates. How much tariffs are weighing on the calculations of insurers will become a bit more clear on Aug. 1, Axios notes, when proposed 2026 premium rates are posted.
Yahoo
4 hours ago
- Yahoo
Treace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the company
Institutions' substantial holdings in Treace Medical Concepts implies that they have significant influence over the company's share price 52% of the business is held by the top 7 shareholders 25% of Treace Medical Concepts is held by insiders Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Treace Medical Concepts, Inc. (NASDAQ:TMCI), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 53% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Treace Medical Concepts. Check out our latest analysis for Treace Medical Concepts Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Treace Medical Concepts does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Treace Medical Concepts, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 9.9% of Treace Medical Concepts shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. With a 19% stake, CEO John Treace is the largest shareholder. Armistice Capital LLC is the second largest shareholder owning 9.9% of common stock, and BlackRock, Inc. holds about 6.1% of the company stock. We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in Treace Medical Concepts, Inc.. Insiders own US$86m worth of shares in the US$343m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public-- including retail investors -- own 12% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Treace Medical Concepts you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
4 hours ago
- Yahoo
"Devastated and heartbroken": Trump cuts LGBTQ+ youth services on 988 suicide hotline
The Trump administration has removed the "Press 3 option" from the national 988 Suicide & Crisis Hotline. The "Press 3 option" was available since 2022 for LGBTQ+ callers looking to speak with a mental health provider specializing in LGBTQ+ mental health care. The service will be shut down formally on July 17. In a statement released on Tuesday, the Substance Abuse and Mental Health Services Administration (SAMHSA) said it was ending the service to "focus on all help seekers, including those previously served through the Press 3 option." The statement also said that the hotline will "no longer silo" what it called "LGB+ services," notably missing the T. "I am devastated and heartbroken," said Jaymes Black, CEO of advocacy organization The Trevor Project, in a video posted to Instagram. "Half a million LGBTQ young people reached out to 988 last year and pressed 3," Black said. "They found trained hearts waiting to help." Black described the "lifeline" for youths in crisis as being "cut" by SAMHSA. The Trevor Project was the contracted third party used by the hotline to provide the "press 3 option." In its statement, SAMHSA noted that the federally allocated $33 million for the option in 2024 was entirely spent by June 2025. It describes the funds as having gone to "support the subnetworks" of the service. "Your life has meaning," Black said in the video, speaking to LGBTQ+ youth. "You are our future, and we will never stop fighting for you."
